OraSure Technologies (NASDAQ:OSUR) Shares Break Above Two Hundred Day Moving Average - Here's Why

Key Points

• OraSure shares moved above their 200-day moving average, trading as high as $3.61 and last at $3.56, versus the average of $3.54.
• Q3 adjusted loss of $0.15 per share was narrower than analysts’ expected $0.20 loss; revenue of $30.91 million was roughly in line with estimates.
• The company’s outlook was softer: Q4 and full-year 2026 revenue forecasts were slightly below consensus, and cash-flow break-even was pushed to the second half of 2027. An agreement with activist investor Altai Capital eased the risk of a proxy fight.

OraSure Technologies, Inc. (NASDAQ:OSUR - Get Free Report)'s share price passed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $3.54 and traded as high as $3.61. OraSure Technologies shares last traded at $3.56, with a volume of 713,141 shares traded.

Key Stories Impacting OraSure Technologies

These are some of the OSUR stories that stood out recently:

• Positive Sentiment: OraSure reported Q3 2026 adjusted earnings per share of a loss of $0.15, better than the consensus estimate of a loss of $0.20. Revenue of $30.91 million was close to the $31.0 million estimate. OraSure Q3 2026 Earnings Call Transcript
• Positive Sentiment: The company reached an agreement with activist investor Altai Capital, reducing the prospect of a costly proxy battle and easing a source of uncertainty for investors. OraSure activist agreement
• Negative Sentiment: Management forecast Q4 revenue of $30 million-$32 million and FY 2026 revenue of $120.4 million, both slightly below analyst consensus of $31.8 million and $121.5 million, respectively. The company also pushed its expected cash-flow break-even timing to the second half of 2027, which could weigh on expectations for profitability and cash use. OraSure Q4 outlook and break-even timing

Analyst Ratings Changes

OSUR has been the subject of several recent research reports. Zacks Research raised shares of OraSure Technologies to a "hold" rating in a report on Friday, October 2nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of OraSure Technologies in a research note on Tuesday, September 1st. Wall Street Zen raised shares of OraSure Technologies from a "sell" rating to a "hold" rating in a report on Monday, August 10th. Finally, Craig Hallum upgraded shares of OraSure Technologies to a "strong-buy" rating in a research report on Friday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold".

OraSure Technologies Stock Performance

The company has a 50 day simple moving average of $3.72 and a 200 day simple moving average of $3.54. The company has a market capitalization of $245.53 million, a PE ratio of -5.16 and a beta of 1.08.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) last issued its earnings results on Monday, November 9th. The medical instruments supplier reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.05. The business had revenue of $30.91 million for the quarter, compared to analysts' expectations of $31.00 million. OraSure Technologies had a negative return on equity of 19.81% and a negative net margin of 41.73%. As a group, equities research analysts anticipate that OraSure Technologies, Inc. will post -0.96 EPS for the current year.

Institutional Investors Weigh In On OraSure Technologies

Institutional investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC increased its holdings in shares of OraSure Technologies by 4.6% in the 1st quarter. Hsbc Holdings PLC now owns 141,309 shares of the medical instruments supplier's stock valued at $421,000 after acquiring an additional 6,218 shares during the period. Legal & General Group Plc purchased a new position in OraSure Technologies in the second quarter worth $30,000. Russell Investments Group Ltd. lifted its holdings in OraSure Technologies by 11.0% in the third quarter. Russell Investments Group Ltd. now owns 79,651 shares of the medical instruments supplier's stock valued at $312,000 after acquiring an additional 7,897 shares during the period. Diversify Advisory Services LLC acquired a new stake in OraSure Technologies in the second quarter valued at $47,000. Finally, Diversify Wealth Management LLC acquired a new stake in OraSure Technologies in the first quarter valued at $36,000. Hedge funds and other institutional investors own 93.50% of the company's stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc. develops, manufactures and markets diagnostic products and specimen-collection technologies used by healthcare providers, laboratories, researchers and consumers. The company focuses on making testing more accessible through products that support decentralized, point-of-care and at-home testing, as well as laboratory-based molecular and diagnostic workflows. Its portfolio has included the OraQuick line of rapid diagnostic tests, including oral-fluid tests for HIV and hepatitis C, along with other infectious-disease testing products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.